MediConnect
MediConnect (MEDI)
More on ICO
Pre-Sale Jan. 16, 2019 - Feb. 6, 2019
Token Sale Feb. 20, 2019 - April 3, 2019
ICOMarks Rating 4.6 / 10 TrackICO Rating 3.7 / 5
Whitelist/KYC Whitelist
Token price 0.1 USD
Platform Stratis

MediConnect is the only blockchain solution intended to revolutionize the use of medication in the UK. It will prevent the over-prescribing to patients of medication from multiple pharmacies, reduce addiction, provide traceability of drugs from manufacturers, wholesalers, prescribers and pharmacies all the way through to patients. This will enable the removal of false medicines and the easy recall of drugs within the Pharma system.

The Safety Net for Patients, Prescribers, Pharmacies and Drug Manufacturers.
With all the regulatory bodies within the Pharmacy sector recognizing and concerned about the growing issue of over-prescribing of prescription medication online, MediConnect can offer a solution to this growing problem almost immediately.

Prescribers & pharmacies using MediConnect will have the confidence that by using our blockchain solution, the misuse and over-prescribing of prescription medication to potential addicts – who would normally shop around online for medication – will be eliminated.

Patients will be given the assurance that the medication they are being prescribed is genuine and from a licensed manufacturer, prescriber and pharmacy that is using a gold-standard solution to help improve their own duty of care.

Q1-2019

ICO Public Sale.
PDA Working Group meeting – Invites to attend to CQC, MHRA, GPhC, LPC, Pharma wholesale and retail industry.

Q2-2019

Commence contract with the ASC to support the Nottingham Trial and UK roll out programme.
Tower Pharmacy & UK Meds will be first 2 Pharmacies on the ASC blockchain solution from MediConnect.
6 other Pharmacies will be integrated, including 1 NHS Hospital outpatient dispensing pharmacy.

Q3-2019

Collaboration with Local Pharmacy Groups and membership committee to inform on pilot and expand reach to 20 further pharmacies in Nottingham, Derby & Leicester.
Partnership with Pharmacy Wholesaler – implementation of drug recall and counterfeit medication system.

Q4-2019

Publish trial research and outcomes – present at PDA meeting to CQC, MHRA. GPhC, LPC and Industry.

Q1-2020

The MediConnect platform will demonstrate an improved duty of care and detection that will see a reduction in pharmacy insurance for Pharmacies.

Q2-2020

Will see the recruitment of 500 UK Pharmacies join MediConnect through the expansion of the ASC membership in the UK.

Q3-2020

Aim for MediConnect to be the Industry standard solution for traceability of drugs for recall and counterfeit medication detection.

Q4-2020

The ASC achieves it’s goal of UK Pharmacies required to be members of the ASC and the MediConenct platform is used by all UK pharmacies.